Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Biovie Inc

(OTHER OTC: BIVI)
Add to Portfolio
+0.0200 (+36.36%)
as of Sep 18, 2019

Last 0.0750
Change +0.0200 (+36.36%)
Open 0.0775
Prev. Close 0.0550
Today's Range
0.0600
0.0775
52wk Range
0.0526
17.5000
Volume 16,700
Avg Volume 54,050
Sector All Sectors By Industry

Perfomance Comparison

Name Today 3-Month 1-Year
BIVI +36.36% -99.37% -99.13%
DJIA +0.13% +1.36% +3.43%
S&P 500 +0.03% +0.91% +3.53%

Key Statistics

Annual EPS N/A
Dividend Yield N/A
P/E Ratio N/A
Market Capitalization, $K N/A
Weighted Alpha -73.90
Standard Deviation +1.72
Profit Margin N/A
Beta N/A

Growth Rates

YTD -97.86%
1-Year -99.14%
3-Year -99.79%
5-Year -99.80%

Opinion

Sell Hold Buy

Recent Headlines

BriaCell Appoints Richard J. Berman to Board of

GlobeNewswire via COMTEX - Mon Aug 12, 06:30AM EDT
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced that it has appointed M(full story)
BCTXF: 0.0481 (-0.0054), ADXS: 0.35 (+0.06), IMRN: 2.84 (+0.01), CATS: 17.37 (+0.16), CYRX: 17.78 (-0.01), BCT.VN: 0.065 (unch), BIVI: 0.0750 (+0.0200)

BioVie Achieves Primary Objectives in Phase 2a

GlobeNewswire via COMTEX - Tue Apr 30, 08:00AM EDT
BioVie Inc. (OTCQB: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for liver disease, today announced top-line results for its Phase 2a clinical trial of BIV201 (continuous infusion te(full story)
BIVI: 0.0750 (+0.0200)

BioVie to Present at ThinkEquity Conference in NYC on

GlobeNewswire via COMTEX - Wed Apr 24, 07:00AM EDT
BioVie Inc. (OTCQB: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for liver disease, announced that Mr. Terren Peizer, the Company's Chairman and CEO, is scheduled to participate in t(full story)
BIVI: 0.0750 (+0.0200)

BioVie Completes Patient Enrollment for its Phase 2a

GlobeNewswire via COMTEX - Wed Feb 06, 08:00AM EST
BioVie Inc. (OTCQB: BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for liver disease, announced today that it has completed enrollment in a Phase 2a open-label clinical study of BI(full story)
BIVI: 0.0750 (+0.0200)